Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07298863

The Effect of Hydration Status on Substrate Oxidation at Rest and During Light and Moderate Exercise

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
74 (estimated)
Sponsor
PepsiCo Global R&D · Industry
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

Metabolic flexibility is the ability to properly switch between fat and carbohydrate stores to use for energy under different conditions (rest, feeding, exercise). Impairments in metabolic flexibility, also known as metabolic inflexibility, have been suggested to be an underlying cause of metabolic disease, like type 2 diabetes. Long-term low fluid intake may increase the risk of type 2 diabetes due to insulin resistance, a form of metabolic inflexibility. Further, low fluid intake has been shown to impair the ability to switch fuel preference during exercise. While there is some evidence that low fluid intake may lead to impaired metabolic flexibility, more information is needed. Therefore, the purpose of this study is to evaluate the impact of hydration status on substrate preference at rest and during exercise at varying intensities (light and moderate). Further, we will examine whether biological sex and menstrual cycle phase impact hydration and metabolism under these same conditions.

Detailed description

The 3-arm intervention will be completed in females during both the follicular and luteal phases for a total of 13 visits including the medical screening. In males, the 3-arm intervention will be completed once for a total of 7 visits including the medical screening.

Conditions

Interventions

TypeNameDescription
OTHERExercise TrialPerform steady-state cycling exercise for approximately 1 hour at 70-80% of maximal heart rate
OTHERExperimental Trial24h after exercise trial, following assigned 24h hydration plan, perform indirect calorimetry followed by 30 min of light cycling (\~50% VO2 max) then 30 min of moderate-high cycling (\~80% VO2 max).

Timeline

Start date
2025-11-05
Primary completion
2026-04-01
Completion
2026-04-30
First posted
2025-12-23
Last updated
2026-03-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07298863. Inclusion in this directory is not an endorsement.